Axillary lymphadenopathy: a complication of BCG immunotherapy for melanoma.
We present a patient with a Clark level IV melanoma who received BCG immunotherapy by scarification for 12 months after wide excision. Six months after cessation of treatment, the patient developed regional lymphadenopathy that histology showed to be reactive epithelioid granuloma. Regional immunotherapy thus represents a potentially confusing factor in the post-operative assessment and management of the patient with melanoma.
Briggs
P C
PC
Division of Plastic Surgery, Allegheny General Hospital, Pittsburgh, Pa.
Heckler
F R
FR
D001365:Axilla; D001500:BCG Vaccine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008206:Lymphatic Diseases / Q000209:etiology* / Q000473:pathology; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000628:therapy*
D001500:BCG Vaccine